- Home
- GCTK vs RDHL Comparison
GCTK vs RDHL Comparison
Compare GCTK & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTK
- RDHL
- Stock Information
- Founded
- GCTK 2001
- RDHL 2009
- Country
- GCTK United States
- RDHL Israel
- Employees
- GCTK N/A
- RDHL N/A
- Industry
- GCTK Medical/Dental Instruments
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- GCTK Health Care
- RDHL Health Care
- Exchange
- GCTK Nasdaq
- RDHL Nasdaq
- Market Cap
- GCTK 5.1M
- RDHL 6.8M
- IPO Year
- GCTK N/A
- RDHL N/A
- Fundamental
- Price
- GCTK $0.38
- RDHL $3.02
- Analyst Decision
- GCTK
- RDHL
- Analyst Count
- GCTK 0
- RDHL 0
- Target Price
- GCTK N/A
- RDHL N/A
- AVG Volume (30 Days)
- GCTK 1.5M
- RDHL 142.7K
- Earning Date
- GCTK 03-27-2025
- RDHL 04-07-2025
- Dividend Yield
- GCTK N/A
- RDHL N/A
- EPS Growth
- GCTK N/A
- RDHL N/A
- EPS
- GCTK N/A
- RDHL N/A
- Revenue
- GCTK N/A
- RDHL $3,707,000.00
- Revenue This Year
- GCTK N/A
- RDHL $224.90
- Revenue Next Year
- GCTK N/A
- RDHL $82.69
- P/E Ratio
- GCTK N/A
- RDHL N/A
- Revenue Growth
- GCTK N/A
- RDHL N/A
- 52 Week Low
- GCTK $0.31
- RDHL $3.01
- 52 Week High
- GCTK $99.00
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- GCTK 29.14
- RDHL 17.60
- Support Level
- GCTK $0.31
- RDHL $3.01
- Resistance Level
- GCTK $0.39
- RDHL $3.47
- Average True Range (ATR)
- GCTK 0.05
- RDHL 0.45
- MACD
- GCTK 0.15
- RDHL -0.09
- Stochastic Oscillator
- GCTK 45.83
- RDHL 0.73
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.